- Home
- INHD vs NRSN Comparison
INHD vs NRSN Comparison
Compare INHD & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INHD | NRSN |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1M | 26.4M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INHD | NRSN |
|---|---|---|
| Price | $1.39 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.5M | 335.2K |
| Earning Date | 12-15-2025 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,846,250.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $0.76 |
| 52 Week High | $474.72 | $2.60 |
Technical Indicators
Market Signals| Indicator | INHD | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 71.39 | 34.74 |
| Support Level | $0.06 | $0.76 |
| Resistance Level | $2.00 | $0.91 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 67.48 | 10.78 |
Price Performance
Historical ComparisonAbout INHD Inno Holdings Inc.
Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.